David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus, entering the clinic in the radiopharma space next year and pouring cold water on IPO talk (for now).
Brought to you by
Also look for unique social pages for BiotechTV U.
Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.
.png){kind=logo}
